公司資料
Arcturus Therapeutics Holdings Inc. 股價、新聞與催化劑
- 股票代碼:
- ARCT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
13.21 USD (-3.51%)
收盤價
最後更新: 2026年10月1日
217M USD
市值
股價為何變動
截至 2026年10月1日，ARCT 下跌 3.51%，收於 $13.21。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Messenger RNA Medicines Company
Arcturus Therapeutics develops mRNA medicines for respiratory and liver diseases. Its platform combines LUNAR lipid-mediated delivery, STARR self-amplifying RNA technology, and internal drug-substance and drug-product manufacturing expertise.
Inhaled mRNA for Cystic Fibrosis
ARCT-032 is an inhaled mRNA therapy designed to express functional CFTR protein in the lungs of people with cystic fibrosis, including those with Class I mutations who may not respond to current modulators. The program is being evaluated through daily inhaled dosing in a Phase 2 study.
Systemic mRNA for OTC Deficiency
ARCT-810 is an intravenously delivered mRNA therapy intended to restore ornithine transcarbamylase activity in people with OTC deficiency. The Phase 2 program includes adult and pediatric development and is intended to inform an end-of-Phase 2 regulatory path.
Self-Amplifying RNA Vaccine Portfolio
KOSTAIVE is the first approved self-amplifying mRNA COVID-19 vaccine and validates the company's STARR platform. Arcturus has regained global control of KOSTAIVE and a broader infectious-disease portfolio that includes influenza, RSV, and EBV programs, subject to existing regional arrangements.
Manufacturing and Development Partnerships
Arcturus works with Thermo Fisher Scientific on potential Phase 3 development and manufacturing for ARCT-032, with BARDA on pandemic influenza initiatives, and through ARCALIS on Japanese mRNA manufacturing. These relationships extend development capacity without requiring the company to build every capability internally.
未來催化劑
- Communication of Phase 2 data and the regulatory plan for ARCT-810 in the third quarter of 2026.
- Decision on advancing ARCT-032 into Phase 3 development in the fourth quarter of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。